Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Go back to Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia| (NASDAQ: CRDF) | Delayed: 0.94 +0.01 (1.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.93 | 52 Week High | $ | |||
| Open | $0.95 | 52 Week Low | $ | |||
| Day High | $0.97 | P/E | N/A | |||
| Day Low | $0.92 | EPS | $ | |||
| Volume | 427,786 | |||||



